Opinion|Videos|May 26, 2025
Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.
Advertisement
Episodes in this series
Lorlatinib’s Unique Adverse Event Profile
Key Themes:
- Cognitive effects, hypercholesterolemia, and peripheral neuropathy with lorlatinib
- Impact of adverse events on treatment selection
- Monitoring and management of cholesterol levels
Notable Insights:
- Dr Dietrich discussed lorlatinib’s unique adverse event profile and its impact on treatment decisions
Dr Lovly outlined best practices for monitoring and managing lorlatinib-induced hypercholesterolemia
Advertisement
Related to this article
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
3
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
4
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
5